134 related articles for article (PubMed ID: 38593589)
1. ML162 derivatives incorporating a naphthoquinone unit as ferroptosis/apoptosis inducers: Design, synthesis, anti-cancer activity, and drug-resistance reversal evaluation.
Ma F; Li Y; Cai M; Yang W; Wu Z; Dong J; Qin JJ
Eur J Med Chem; 2024 Apr; 270():116387. PubMed ID: 38593589
[TBL] [Abstract][Full Text] [Related]
2. Dual degradation mechanism of GPX4 degrader in induction of ferroptosis exerting anti-resistant tumor effect.
Wang C; Zheng C; Wang H; Shui S; Jin H; Liu G; Xu F; Liu Z; Zhang L; Sun D; Xu P
Eur J Med Chem; 2023 Feb; 247():115072. PubMed ID: 36603510
[TBL] [Abstract][Full Text] [Related]
3. Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis In Vivo.
Luo T; Zheng Q; Shao L; Ma T; Mao L; Wang M
Angew Chem Int Ed Engl; 2022 Sep; 61(39):e202206277. PubMed ID: 35924720
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Evaluation for First GPX4 and CDK Dual Inhibitors.
Zhu J; Cai Y; Kong M; Li Y; Zhu L; Zhang J; Yu Z; Xu S; Hong L; Chen C; Luo J; Kong L
J Med Chem; 2024 Feb; 67(4):2758-2776. PubMed ID: 38295524
[TBL] [Abstract][Full Text] [Related]
5. Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells.
Wang H; Wang C; Li B; Zheng C; Liu G; Liu Z; Zhang L; Xu P
Eur J Med Chem; 2023 Jun; 254():115343. PubMed ID: 37087895
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Potent Covalent Glutathione Peroxidase 4 Inhibitors as Highly Selective Ferroptosis Inducers for the Treatment of Triple-Negative Breast Cancer.
Chen T; Leng J; Tan J; Zhao Y; Xie S; Zhao S; Yan X; Zhu L; Luo J; Kong L; Yin Y
J Med Chem; 2023 Jul; 66(14):10036-10059. PubMed ID: 37452764
[TBL] [Abstract][Full Text] [Related]
7. Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells.
Sang J; Liu CK; Liu J; Luo GC; Zheng WJ; Bai Y; Jiang DY; Pu JN; An S; Xu TR
Biochem Pharmacol; 2024 May; 223():116194. PubMed ID: 38583812
[TBL] [Abstract][Full Text] [Related]
8. ROS-responsive fluorinated polyethyleneimine vector to co-deliver shMTHFD2 and shGPX4 plasmids induces ferroptosis and apoptosis for cancer therapy.
Yang S; Wong KH; Hua P; He C; Yu H; Shao D; Shi Z; Chen M
Acta Biomater; 2022 Mar; 140():492-505. PubMed ID: 34879292
[TBL] [Abstract][Full Text] [Related]
9. Novel Covalent Probe Selectively Targeting Glutathione Peroxidase 4 In Vivo: Potential Applications in Pancreatic Cancer Therapy.
Tang Z; Li J; Peng L; Xu F; Tan Y; He X; Zhu C; Zhang ZM; Zhang Z; Sun P; Ding K; Li Z
J Med Chem; 2024 Feb; 67(3):1872-1887. PubMed ID: 38265413
[TBL] [Abstract][Full Text] [Related]
10. A potent GPX4 degrader to induce ferroptosis in HT1080 cells.
Song H; Liang J; Guo Y; Liu Y; Sa K; Yan G; Xu W; Xu W; Chen L; Li H
Eur J Med Chem; 2024 Feb; 265():116110. PubMed ID: 38194774
[TBL] [Abstract][Full Text] [Related]
11. Potent nanoreactor-mediated ferroptosis-based strategy for the reversal of cancer chemoresistance to Sorafenib.
Wang X; Zhao L; Wang C; Wang L; Wu H; Song X; Wang W; Xu H; Dong X
Acta Biomater; 2023 Mar; 159():237-246. PubMed ID: 36736851
[TBL] [Abstract][Full Text] [Related]
12. The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1.
Cheff DM; Huang C; Scholzen KC; Gencheva R; Ronzetti MH; Cheng Q; Hall MD; Arnér ESJ
Redox Biol; 2023 Jun; 62():102703. PubMed ID: 37087975
[TBL] [Abstract][Full Text] [Related]
13. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
14. Significance of glutathione peroxidase 4 and intracellular iron level in ovarian cancer cells-"utilization" of ferroptosis mechanism.
Li D; Zhang M; Chao H
Inflamm Res; 2021 Dec; 70(10-12):1177-1189. PubMed ID: 34537856
[TBL] [Abstract][Full Text] [Related]
15. From DNMT1 degrader to ferroptosis promoter: Drug repositioning of 6-Thioguanine as a ferroptosis inducer in gastric cancer.
Zhang J; Gao M; Niu Y; Sun J
Biochem Biophys Res Commun; 2022 May; 603():75-81. PubMed ID: 35278883
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
[TBL] [Abstract][Full Text] [Related]
17. Prospects for Anti-Tumor Mechanism and Potential Clinical Application Based on Glutathione Peroxidase 4 Mediated Ferroptosis.
Chen M; Shi Z; Sun Y; Ning H; Gu X; Zhang L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675129
[TBL] [Abstract][Full Text] [Related]
18. Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience.
Lee J; Roh JL
Cancer Lett; 2023 Apr; 559():216119. PubMed ID: 36893895
[TBL] [Abstract][Full Text] [Related]
19. ZX703: A Small-Molecule Degrader of GPX4 Inducing Ferroptosis in Human Cancer Cells.
Hu M; Li X; Wang L; Zhang Y; Sun Y; Hua H; Liu H; Cai T; Zhu D; Xiang Q
ACS Med Chem Lett; 2024 Mar; 15(3):406-412. PubMed ID: 38505849
[TBL] [Abstract][Full Text] [Related]
20. Tubastatin A potently inhibits GPX4 activity to potentiate cancer radiotherapy through boosting ferroptosis.
Liu S; Zhang HL; Li J; Ye ZP; Du T; Li LC; Guo YQ; Yang D; Li ZL; Cao JH; Hu BX; Chen YH; Feng GK; Li ZM; Deng R; Huang JJ; Zhu XF
Redox Biol; 2023 Jun; 62():102677. PubMed ID: 36989572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
